Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Acquisitions & Divestments: 2017-2025

Historic Change in Acquisitions & Divestments for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $19.1 million.

  • Aclaris Therapeutics' Change in Acquisitions & Divestments rose 11.20% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year increase of 19.49%. This contributed to the annual value of $86.1 million for FY2024, which is 52.98% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $19.1 million for Q3 2025, which was down 23.79% from $25.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Change in Acquisitions & Divestments registered a high of $70.6 million during Q2 2023, and its lowest value of $8.0 million during Q4 2023.
  • Over the past 3 years, Aclaris Therapeutics' median Change in Acquisitions & Divestments value was $25.0 million (recorded in 2025), while the average stood at $31.2 million.
  • In the last 5 years, Aclaris Therapeutics' Change in Acquisitions & Divestments spiked by 376.81% in 2021 and then tumbled by 83.64% in 2023.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Change in Acquisitions & Divestments stood at $26.3 million in 2021, then soared by 85.56% to $48.8 million in 2022, then crashed by 83.64% to $8.0 million in 2023, then surged by 119.17% to $17.5 million in 2024, then grew by 11.20% to $19.1 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $19.1 million for Q3 2025, versus $25.0 million for Q2 2025 and $30.0 million for Q1 2025.